Anti-Human CD279 Recombinant Antibody(Spartalizumab)

Product Information

Catalog Number	YR1475
Product Name	Anti-Human CD279 Recombinant Antibody(Spartalizumab)
Molecular Name	Spartalizumab
Alias	Anti-CD279 Recombinant Antibody, Research Grade Spartalizumab
CAS Number	1935694-88-4
Target	CD279[Homo sapiens]
Isotype	IgG4 Kappa
Clonity	Monoclonal
Source	CHO Cells
Size	1mg, 5mg
Concentration	1mg/ml
Purity	>95% as determined by SDS-PAGE
Buffer	PBS, pH7.5
Background	Spartalizumab (INN, development code PDR001) is a monoclonal antibody that is being investigated for melanoma. This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials.
Storage	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Note	This product is for research use only.

Cat#	Product Name	Species	Host	Applications	Size	Price